文献速递肿瘤 PET/CT

晚期黑色素瘤患者免疫检查点抑制剂治疗中[18F]FDG PET/CT改良反应标准的预测价值与准确性

Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-05-04

回顾性纳入91例接受免疫检查点抑制剂(ICI)的不可切除IV期黑色素瘤患者,每例治疗前后各行一次[18F]FDG PET/CT,按PERCIMT、PERCIST5和imPERCIST5三种改良标准评估代谢反应并与临床结局比较。PERCIMT与imPERCIST5的疾病控制率显著不同于PERCIST5(P < 0.001),PERCIMT与imPERCIST5之间无显著差异;PERCIMT和PERCIST5的代谢反应组总生存显著长于非反应组,imPERCIST5则未观察到该差异(P = 0.12)。

要点

  • PERCIMT与imPERCIST5的疾病控制率显著不同于PERCIST5(P < 0.001),两者之间无显著差异。
  • PERCIMT标准下代谢反应组总生存2.48年 vs 非反应组1.47年(P = 0.003)。
  • PERCIST5标准下代谢反应组总生存2.57年 vs 非反应组1.81年(P = 0.017)。

核心结论

  • 新病灶出现可能继发于ICI的炎症反应并提示假性进展,但鉴于真性进展率更高,对新病灶的出现应审慎解读。
  • 在三种评估的改良标准中,PERCIMT似乎能提供更可靠的代谢反应评估,且与患者总生存强相关。

研究设计与样本

  • 回顾性纳入91例接受ICI治疗的不可切除IV期转移性黑色素瘤患者。
  • 每例患者均在ICI治疗前后各行一次[18F]FDG PET/CT扫描。
  • 随访扫描按PERCIMT、PERCIST5和imPERCIST5三种标准评估反应,分为完全代谢反应(CMR)、部分代谢反应(PMR)、进展性代谢疾病(PMD)和稳定代谢疾病(SMD)四组。
  • 将CMR、PMR和SMD归为「疾病控制组(即反应者)」,PMD归为「疾病未控制组(即非反应者)」,以评估疾病控制率。

主要发现

  • 按PERCIMT、PERCIST5和imPERCIST5标准,反应率分别为40.7%、41.8%和54.9%,疾病控制率分别为71.4%、50.5%和74.7%。
  • PERCIMT和imPERCIST5的疾病控制率与PERCIST5相比有显著差异(P < 0.001),PERCIMT与imPERCIST5之间无显著差异。
  • 基于PERCIMT标准,代谢反应组总生存2.48年 vs 非反应组1.47年(P = 0.003)。
  • 基于PERCIST5标准,代谢反应组总生存2.57年 vs 非反应组1.81年(P = 0.017)。
  • 基于imPERCIST5标准,代谢反应组与非反应组总生存差异未观察到(P = 0.12)。

关键数值与推荐

  • PERCIMT标准的反应率为40.7%,疾病控制率为71.4%。
  • PERCIST5标准的反应率为41.8%,疾病控制率为50.5%。
  • imPERCIST5标准的反应率为54.9%,疾病控制率为74.7%。

临床怎么用

  • 作者认为,尽管新病灶出现可能继发于ICI的炎症反应并提示假性进展,但鉴于真性进展率更高,出现新病灶时应审慎解读。
  • 作者认为,在三种评估的改良标准中,PERCIMT似乎能提供更可靠的代谢反应评估,且与患者总生存强相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Immune checkpoint inhibitors (ICIs) are widely used in metastatic melanoma and dramatically alter the treatment of these patients. Given the high cost and potential toxicity, a reliable method for evaluating treatment response is needed. In this study, we assessed tumor response in patients with metastatic melanoma treated with ICIs using three modified response criteria: PET Response Evaluation Criteria for Immunotherapy (PERCIMT), PET Response Criteria in Solid Tumors for up to Five Lesions (PERCIST5), and immunotherapy-modified PET Response Criteria in Solid Tumors for up to Five Lesions (imPERCIST5). METHODS: Ninety-one patients with non-resectable stage IV metastatic melanoma who received ICIs were retrospectively enrolled in this study. Each patient had two [18F]FDG PET/CT scans performed before and after ICI therapy. Responses at the follow-up scan were evaluated according to PERCIMT, PERCIST5, and imPERCIST5 criteria. Patients were classified into four groups: complete metabolic response (CMR), partial metabolic response (PMR), progressive metabolic disease (PMD), and stable metabolic disease (SMD). To assess the "disease control rate," two groups have been defined based on each criterion: patients with CMR, PMR, and SMD as "disease-controlled group (i.e., responders)" and PMD as the "uncontrolled-disease group (i.e., non-responders)". The correspondence between metabolic tumor response defined by these criteria and clinical outcome was assessed and compared. RESULTS: The response and the disease control rates were 40.7% and 71.4%, 41.8% and 50.5%, and 54.9% and 74.7% based on the PERCIMT, PERCIST5, and imPERCIST5 criteria, respectively. PERCIMT and imPERCIST5 showed significantly different disease control rates from that of PERCIST5 (P < 0.001), whereas it was not significant between PERCIMT and imPERCIST5. Overall survival was significantly longer in the metabolic responder groups than in the non-responder groups based on PERCIMT and PERCIST5 criteria (PERCIMT: 2.48 versus 1.47 years, P = 0.003; PERCIST5: 2.57 versus 1.81 years. P = 0.017). However, according to imPERCIST5 criterion, this difference was not observed (P = 0.12). CONCLUSION: Although the appearance of new lesions can be secondary to an inflammatory response to ICIs and indicative of pseudoprogression, given the higher rate of true progression, the appearance of new lesions should be interpreted deliberately. Of the three assessed modified criteria, PERCIMT appear to provide more reliable metabolic response assessment that correlates strongly with overall patient survival.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ayati N, Jamshidi-Araghi Z, Hoellwerth M, et al. Predictive value and accuracy of [18F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. Eur J Nucl Med Mol Imaging. 2023. PMID: 37140669. doi:10.1007/s00259-023-06247-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。